GUÍA MANEJO ANTIRRETROVIRAL PERSONAS VIH

32. Aleman S, Söderbärg K, Visco-Comandini U, et al. Drug
resistance at low viraemia in HIV-1-infected patients with
antiretroviral combination therapy. AIDS. 2002;16:1039-1044.
33. Campbell TB, Smeaton LM, Kumarasamy N, et al. Efficacy and
safety of three antiretroviral regimens for initial treatment of HIV-
1: a randomized clinical trial in diverse multinational settings.
PLoS Med 2012; 9(8).
34. Cassetti I, Madruga JV, Etzel A, at al. The safety and efficacy of
tenofovir DF (TDF) in combination with lamivudine (3TC) and
efavirenz (EFV) in antiretroviral-naive patients through seven
years. Paper presented at: 17th International AIDS Conference;
2008; Mexico City, Mexico.
35. Daar ES, Tierney C, Fischl MA, et al. Atazanavir plus ritonavir or
efavirenz as part of a 3-drug regimen for initial treatment of HIV-
1. Ann Intern Med. 2011;154(7):445-456.
36. DeJesus E, Herrera G, Teofilo E, et al. Abacavir versus zidovudine
combined with lamivudine and efavirenz, for the treatment of
antiretroviral-naive HIV-infected adults. Clin Infect Dis.
2004;39(7):1038-1046.
37. DeJesus E, Rockstroh JK, Henry K, et al. Co-formulated
elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil
fumarate versus ritonavir-boosted atazanavir plus co-formulated
emtricitabine and tenofovir disoproxil fumarate for initial
treatment of HIV-1 infection: a randomised, double-blind, phase
3, non-inferiority trial. Lancet. 2012;379(9835):2429-2438
38. DeJesus E, Rockstroh JK, Lennox JL, et al. Efficacy of raltegravir
versus efavirenz when combined with tenofovir/emtricitabine in
treatment-naive HIV-1-infected patients: week-192 overall and
subgroup analyses from STARTMRK. HIV Clin Trials.
2012;13(4):228-232
39. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF,
emtricitabine, and efavirenz vs. zidovudine, lamivudine, and
efavirenz for HIV. N Engl J Med. 2006;354(3):251-260.
40. German P, Liu HC, Szwarcberg J, et al. Effect of cobicistat on
glomerular filtration rate in subjects with normal and impaired
renal function. J Acquir Immune Defic Syndr. 2012;61(1):32-40.
41. Goicoechea M, Liu S, Best B, et al. Greater tenofovir-associated
renal function decline with protease inhibitor-based versus
nonnucleoside reverse-transcriptase inhibitor-based therapy. J
Infect Dis. 2008;197(1):102-108.
42. Landovitz RJ RH, Ofotokun I, et al. Efficacy and tolerability of
atazanavir, raltegravir or darunavir with FTC/tenofovir: ACTG
5257. Abstract 85. Paper presented at the 21st Conference on
Retroviruses and Opportunistic Infections; March 3–6, 2014;
Boston, MA.
43. Lathouwers E, De Meyer S, Dierynck I, et al. Virological
characterization of patients failing darunavir/ritonavir or
lopinavir/ritonavir treatment in the ARTEMIS study: 96-week
analysis. Antivir Ther. 2011;16(1):99-108.
44. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of
raltegravir-based versus efavirenz-based combination therapy in
treatment-naive patients with HIV-1 infection: a multicentre,
double-blind randomised controlled trial. Lancet.
2009;374(9692):796-806.
45. Lennox JL, DeJesus E Berger DS, et al. Raltegravir vs efavirenz
regimen in treatment-naïve HIV-1 infected patients: 96 week
efficacy, durability, subgroup, safety and metabolic analysis. J
Acquir Immune Defic Syndr. 2010;55:39-42.
46. McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and
fractures in antiretroviral-naive persons randomized to receive
abacavir-lamivudine or tenofovir disoproxil fumarateemtricitabine
along with efavirenz or atazanavirritonavir: Aids
Clinical Trials Group A5224s, a substudy of ACTG A5202. J
Infect Dis. 2011;203(12):1791-1801.
47. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily
atazanavir/ritonavir compared with twice-daily
lopinavir/ritonavir, each in combination with tenofovir and
emtricitabine, for management of antiretroviral-naive HIV-1-
infected patients: 96-week efficacy and safety results of the
CASTLE study. J Acquir Immune Defic Syndr. 2010;53(3):323-
332.
48. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily
atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each
in combination with tenofovir and emtricitabine, for management
of antiretroviral-naive HIV-1-infected patients: 48 week efficacy
and safety results of the CASTLE study. Lancet.
2008;372(9639):646-655.
49. Molina JM, Podsadecki TJ, Johnson MA, et al. A
lopinavir/ritonavir-based once-daily regimen results in better
compliance and is non-inferior to a twice-daily regimen through
96 weeks. AIDS Res Hum Retroviruses. 2007;23(12):1505-
1514.
50. Murphy RL, da Silva BA, Hicks CB, et al. Seven-year efficacy of a
lopinavir/ritonavir-based regimen in antiretroviralnaive HIV-1-
infected patients. HIV Clin Trials. 2008;9(1):1-10.
51. Orkin C, Arribas JR, et al. Comparison of changes in bone density
and turnover with abacavir-lamivudine versus tenofoviremtricitabine
in HIV-infected adults: 48-week results from the
ASSERT study. Clin Infect Dis. 2010;51(8):963-972.
52. Orkin C, Dejesus E, Khanlou H, et al. Final 192-week efficacy and
safety of once-daily darunavir/ritonavir compared with
lopinavir/ritonavir in HIV-1-infected treatment-naive patients in
the ARTEMIS trial. HIV Med. 2013;14(1):49-59.
53. Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of oncedaily
darunavir/ritonavir versus lopinavir/ritonavir in treatmentnaive
HIV-1-infected patients at week 48. AIDS.
2008;22(12):1389-1397.
54. Post FA, Moyle GJ, Stellbrink HJ, et al. Randomized comparison
of renal effects, efficacy, and safety with once-daily
abacavir/lamivudine versus tenofovir/emtricitabine,
administered with efavirenz, in antiretroviral-naive, HIV-1-
infected adults: 48-week results from the ASSERT study. J Acquir
Immune Defic Syndr. 2010;55(1):49-57.
55. Puls RL, Srasuebkul P, Petoumenos K, et al. Efavirenz versus
boosted atazanavir or zi-dovudine and abacavir in antiretroviral
treatment-naive, HIV-infected subjects: week 48 data from the
Altair study. Clin Inf Dis 2010;51(7):855-64.
56. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing
regimens for initial treatment of HIV-1 infection. N Engl J Med.
2008;358(20):2095-2106.
57. Rockstroh JK, DeJesus E, Lennox JL, et al. Durable efficacy and
safety of raltegravir versus efavirenz when combined with
tenofovir/emtricitabine in treatment-naive HIV-1-infected
patients: final 5-year results from STARTMRK. J Acquir Immune
Defic Syndr. 2013;63(1):77-85
58. Sax P, Tierney C, Collier AC, al. e. Abacavir-lamivudine versus
tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med.
2009;361.
59. Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir,
cobicistat, emtricitabine, and tenofovir versus coformulated
efavirenz, emtricitabine, and tenofovir for initial treatment of
HIV-1 infection: a randomised, double-blind, phase 3 trial,
analysis of results after 48 weeks. Lancet. 2012;379(9835):2439-
2448.
60. Sax PE, Tierney C, Collier AC, et al. Abacavir/Lamivudine Versus
Tenofovir DF/Emtricitabine as Part of Combination Regimens for
Initial Treatment of HIV: Final Results. J Infect Dis.
2011;204(8):1191-1201.
61. Shubber Z, Calmy A, Andrieux-Meyer I, et al. Adverse events
associated with nevirapine and efavirenz-based first-line
antiretroviral therapy: a systematic review and meta-analysis.
AIDS 2013; 27(9): 1403-12.
62. Sierra-madero J, Villasis-keever A, Me P, et al. Prospective,
Randomized, Open Label Trial of Efavirenz vs Lopinavir /
Ritonavir in HIV + Treatment-Naive Subjects. J Acquir Immune
Defic Syndr 2010;53(5):582-588.
63. Smith KY, Patel P, Fine D, et al. Randomized, double-blind,
placebo-matched, multicenter trial of abacavir/lamivudine or
tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV
treatment. AIDS. 2009;23(12):1547-1556.
64. Soriano V, Arastéh K, Migrone H, et al. Nevirapine versus
atazanavir/ritonavir, each combined with tenofovir disoproxil
fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients:
the ARTEN Trial. Antiv Ther 2011;16(3):339-48.
65. Trottier B, Machouf N, Thomas R, et al. Abacavir/lamivudine
fixed-dose combination with ritonavir-boosted darunavir: a safe
and efficacious regimen for HIV therapy. HIV Clin Trials.
2012;13(6):335-342.
66. Young B, Vanig T, Dejesus E, et al. A pilot study of
abacavir/lamivudine and raltegravir in antiretroviral-naive HIV-
1-infected patients: 48-week results of the SHIELD trial. HIV Clin
Trials. 2010;11(5):260-269.
67. Zolopa A, Sax PE, DeJesus E, et al. A randomized double-blind
comparison of coformulated
elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil
fumarate versus efavirenz/emtricitabine/tenofovir disoproxil
fumarate for initial treatment of HIV-1 infection: analysis of week
96 results. J Acquir Immune Defic Syndr. 2013;63(1):96-100
68. Campbell TB. Choice of an initial antiretroviral regimen in the
resource-limited setting: the cost of virologic failure. Clin Infect
Dis. 2008;47:723-5.
69. Calva JJ, Sierra J, Soto LE, et al. The Successful Application of a
National Peer Advisory Committee for Physicians who Provide
Salvage Regimens to Heavily Antiretroviral Experienced Patients
173